NeoGenomics launches NGS assay for AML

Leukemia & Lymphoma Society renamed Blood Cancer United

The Leukemia & Lymphoma Society is becoming Blood Cancer United on August 28 in advance of Blood Cancer Awareness Month in September.

August 01, 2025

Vol.51 No.30

Clinical Roundup

IGRT shows no reduction in serious infections for patients with CLL

Regular treatment with immunoglobulin replacement therapy in patients with chronic lymphocytic leukemia was not associated with a reduced risk of serious infections requiring hospitalization, according to a study published in Blood Advances.

August 01, 2025

Vol.51 No.30

Drugs & Targets

China’s NMPA approves lisaftoclax for CLL or SLL

The National Medical Products Administration in China approved lisaftoclax (APG-2575), a Bcl-2 selective inhibitor, for the treatment of adult patients with chronic lymphocytic leukemia/small lymphocytic lymphoma who have previously received at least one systemic therapy including Bruton’s tyrosine kinase (BTK) inhibitors.

July 11, 2025

Vol.51 No.27

In Brief

Multi-institutional team awarded $3.4M NCI grant to open AML trial

The University of Cincinnati Cancer Center, The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Jabez Biosciences are partnering to open a new phase I clinical trial studying JBZ-001, a potential new treatment for acute myeloid leukemia.

June 27, 2025

Vol.51 No.25

In Brief

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

Brian Druker ran the marathon with his daughter, Julia, to celebrate her May 2025 college graduation and law school applications (The Cancer Letter, April 4, 2025).

May 02, 2025

Vol.51 No.17

Clinical Roundup

Genetic mutations link could lead to new therapies for AML

Researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute and Memorial Sloan Kettering Cancer Center in New York have found a link between two genetic mutations in a subtype of acute myeloid leukemia, which could lead to new ways to treat the disease.

April 25, 2025

Vol.51 No.16

NeoGenomics launches NGS assay for AML

YOU MAY BE INTERESTED IN

Leukemia & Lymphoma Society renamed Blood Cancer United

IGRT shows no reduction in serious infections for patients with CLL

China’s NMPA approves lisaftoclax for CLL or SLL

Multi-institutional team awarded $3.4M NCI grant to open AML trial

Brian Druker, developer of Gleevec, crosses Boston Marathon finish line alongside daughter Julia

Genetic mutations link could lead to new therapies for AML

Renew today!

Subscriber content

Never miss an issue!

Login